Alli exhibit to tour nationwide
PITTSBURGH —Alli’s hitting the road.
GlaxoSmithKline Consumer Healthcare last month launched its “Alli Experience” mall tour, an educational exhibit that will make stops in 12 major U.S. cities to help educate overweight adults on healthy weight-loss strategies, as well as introduce them to the Alli program.
“Based on consumers’ positive feedback of the ‘Alli Experience,’ the initial installation in New York earlier this year where more than 10,000 people visited in 19 days, we have decided to continue the momentum and take that unique experience to others across the United States,” stated Steven Burton, vice president of weight control at GlaxoSmithKline Consumer Healthcare. “We want to make sure as many people as possible have a chance to experience this unique educational exhibit, which will provide them with extremely useful information on the Alli program so they can make a fully-informed decision whether they are ready to commit to trying Alli.” The multimedia exhibit, divided into three zones, encourages visitors to embrace a more realistic approach to diet and exercise for improved health:
Zone 1 (“You”): In this area visitors can learn about empowerment and how to take the first step toward weight loss.
Zone 2 (“Food”): Visitors are then greeted by a registered dietician who can provide tips for healthy eating and strategies for safe weight loss.
Zone 3 (“Alli”): In the final zone, consumers learn more about the product through a number of interactive stations. This area helps visitors find out if they are ready for a true weight-loss commitment or still hoping for a quick fix. They can ask a pharmacist questions about taking Alli while on other medications. They also can learn how Alli can help them lose 50 percent more weight than dieting alone.
Alli tops in three-and-a-half months| Sales* | Percent change | |
| Alli | $65.0** | NA |
| Hydroxycut | 33.8 | 27.4% |
| Relacore | 18.1 | -20.3 |
| Zantrex3 | 14.1 | -6.3 |
| Slimquick | 12.2 | 27.8 |
| Overall | 339.4 | 19.4 |
Launched June 15, Alli (orlistat 60 mg) is the only Food and Drug Administration-approved weight-loss product available to overweight adults without a prescription, and it is already the leading weight-loss diet aid in mass outlets. For the 52 weeks ended Sept. 9, diet aid tablets generated $339.4 million across food, drug and mass retailers (minus Wal-Mart), according to Information Resources Inc. Sales of Alli accounted for almost 20 percent of that total.
For specifics about the “Alli Experience,” visit www.myalli.com/tour/index.html.